Next-generation sequencing has revolutionized clinical laboratory diagnostics; however, it is not without its challenges. One of the main shortcomings of clinical laboratories using this technology is interpretion of the variants identified. International efforts are aimed at reclassification of variants of unknown significance (VUS) 2 as deleterious or benign, based on available data such as allelic frequency in a control population, conservation of the amino acid, in silico predictors, and published functional assays. However, these efforts have their limitations. A recent article in Nature Medicine by Tsai et al.
(1 ) discusses a recent technology called genome editing as a relatively quick, simple, and costeffective way to reclassify VUS. Briefly, genome editing, via the Cas9 system, allows RNA-guided DNA nuclease enzyme to induce site-directed double-strand breaks in DNA sequences of interest followed by either nonhomologous end-joining (NHEJ) repair or homology-directed repair (HDR). NHEJ or HDR can lead to efficient introduction of insertion/deletion mutations of varying sizes or precise sequence changes using a donor template, respectively. This system allows genome editing to be performed in situ with a very high efficiency and without the need for drug selection markers.
The article by Tsai et al. proposes that this genome editing technology could be used to elucidate the pathogenicity of the variants detected in a clinical setting (1 ) . First, genome editing could be useful in determining whether a variant is playing a causative role (pathogenic) or not (benign). For instance, a recent study using this technology introduced knockout mutations in Pten and Trp53 in vivo in adult mouse liver, which resulted in tumor formation. Second, drug resistance mutations could be studied with this technology. For example, genome editing in a human embryonic kidney cell line introduced specific mutations that allowed identification of those that result in resistance to triptolide, a drug being studied for the treatment of pancreatic cancer. A third way this technology could be useful is in studying combinatorial effects of multiple variants. An example of this has been performed by introducing mutations in multiple genes important in hematopoiesis in a mouse model, which led to mice developing acute myeloid leukemia.
Although genome editing technologies have their limitations (discussed in the article), Tsai et al. highlight
